Alzprotect

Alzprotect is a biopharmaceutical company that develops drug candidates, from discovery to clinical trials, for the treatment of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and tauopathies such as Progressive Supranuclear Palsy. The company was founded in 2007 by Prof. André Delacourte and Prof. Patricia Melnyk and was first established at the Jean-Pierre Aubert Institute in Lille, France. Its lead molecule, AZP2006 (Ezeprogind®), acts on known markers of neurodegeneration including Amyloid beta peptide, Tau protein, neuroinflammation and oxidative stress.

Alzprotect was founded in 2007 by Prof. André Delacourte, PhD, a pioneer in the molecular characterization of neurodegenerative diseases, and Prof. Patricia Melnyk, PhD, an expert in medicinal chemistry. The company was first established at the Jean-Pierre Aubert Institute in Lille, France. Its initial research strategy explored the potential of antimalarial molecules to redirect amyloid precursor protein (APP) processing toward non-amyloidogenic pathways. From this work, AZP2006 was identified in 2010 as the lead candidate after screening several hundred compounds under industry standards. Preclinical studies conducted between 2010 and 2011 revealed that AZP2006 could significantly reduce Tau hyperphosphorylation in the Thy-Tau22 mouse model.

Biopharmaceutical company specialized in neurodegeneration and tauopathies

• AZP2006 (Ezeprogind®)

  Lead drug candidate with a novel mechanism of action acting on Amyloid beta peptide, Tau protein, neuroinflammation and oxidative stress, developed for tauopathies including Progressive Supranuclear Palsy and Alzheimer's disease.

1. 1Alzprotect - Homepagealzprotect.com
2. 2Alzprotect - A biotech company specialized in neurodegeneration and tauopathiesalzprotect.com
3. 3Alzprotect - A multidisciplinary team with expertise in neurodegenerationalzprotect.com